Colchicine Alleviates Non-Atherosclerotic Vascular Aging by Targeting Endothelial Dysfunction and Inflammatory Status

Read full text
Authors: Soroush Mohammadi Jouabadi, Annika A. Jüttner, Keivan Golshiri, Ehsan Ataei Ataabadi, Martine de Boer, René R. P. de Vries, Richard van Veghel, Yoëlle Goos, Youri Boon, Usha M. Musterd‐Bhaggoe, Dirk Duncker, Antoinette MaassenVanDenBrink
+4 more A.H. Jan Danser, Willem Bax, J H Cornel, Anton J.M. Roks
Cited by: 1
References: 38

Abstract

Background: Non-atherosclerotic vascular aging (NAVA) contributes to cardiovascular risk through progressive arterial stiffening and endothelial dysfunction. Colchicine, best known for anti-inflammatory activity, has been proposed to protect vascular structure and function. We evaluated whether chronic colchicine mitigates NAVA in a smooth-muscle-specific ERCC1 knockout (SMC-KO) mouse model of DNA-damage-driven vascular aging. Methods: We performed experiments in the SMC-KO treated with colchicine (0.1mg/kg/day) or vehicle from the age of 10 to 22 weeks. Endothelial function was assessed by acetylcholine-induced vasorelaxation, and vascular structure by pulse-wave velocity (PWV), carotid intima-media thickness (cIMT), and elastin integrity. Results: SMC-KO mice developed increased arterial stiffness and impaired acetylcholine-mediated relaxation. Chronic colchicine significantly (p

Fields of Study & Subjects

Inflammasome and immune disorders Cardiovascular Health and Disease Prevention Metabolomics and Mass Spectrometry Studies

Publication details

Journal / source
Journal of Inflammation Research
Publisher
Informa UK Limited
Volume
Volume 19
Pages
1–15
Publication date
1 February 2026
Language
EN